Intradermal exosomes, platelet-rich plasma, and steroid injections for post-herpetic neuralgia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This randomized controlled trial will enroll 45 adults with dermatomal pain persisting at least 90 days after herpes zoster and randomly assign them to receive intradermal exosome injections, intradermal autologous PRP injections, or intradermal triamcinolone acetonide injections. Each participant will receive four treatment sessions spaced two weeks apart, with outcomes measured at baseline, after the final session, and at 3- and 6-month follow-up visits. Primary outcomes include changes in pain severity and neuropathic pain characteristics, and secondary outcomes include quality of life, patient satisfaction, and adverse events. Safety and tolerability of the injections will be monitored throughout the study.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with post-herpes zoster persistent dermatomal pain consistent with post-herpetic neuralgia for at least 90 days.

Male or female patients. Age 18 years or older. Willingness to comply with study procedures and attend follow-up visits. Ability and willingness to provide written informed consent

Exclusion Criteria:

* History of hypersensitivity to any of the study treatments. Pregnancy. Any type of skin infection involving the affected dermatome. Immunocompromised patients, including patients with cancer or HIV. Patients with bone marrow aplasia. Patients with known bleeding tendency, platelet dysfunction, or thrombocytopenia, defined as platelet count less than 150 × 10⁹/L.

Regular use of anticoagulant or antiplatelet drugs.

Where it's running

• Zagazig University Hospitals
  Zagazig, Zagazig, Egypt Recruiting

Study contacts

• Study coordinator: mona Elradi
• Email: monaelradi@medicine.zu.edu.eg
• Phone: +201067070550

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HL-1186 Tablet for postherpetic neuralgia: safety and efficacy in adults

  This study tests whether HL-1186 tablets, compared with placebo and with pregabalin, help reduce pain in adults with postherpetic neuralgia.

  Recruiting Phase 2 Shanghai Huilun Pharmaceutical Co., Ltd. · Beijing · NCT07758920

• Comparing Pregabalin and Lacosamide for Pain Relief in Shingles Patients

  This study is testing whether Pregabalin or Lacosamide works better to relieve pain in adults aged 18 to 50 who have post-herpetic neuralgia after shingles.

  Recruiting CMH Kharian Medical College · Kharan, Punjab Province · NCT06969417

• Erector spinae plane block versus transcutaneous radiofrequency for postherpetic neuralgia

  This project will see if erector spinae plane block or transcutaneous radiofrequency works better to reduce pain in adults with postherpetic neuralgia.

  Recruiting Diskapi Teaching and Research Hospital · Ankara · NCT07400640

• Transcutaneous pulsed radiofrequency for postherpetic neuralgia pain

  This study will try a non-invasive pulsed radiofrequency treatment applied through the skin to reduce pain in adults with postherpetic neuralgia who have not responded to standard treatments.

  Recruiting Prof. Dr. Cemil Tascıoglu Education and Research Hospital Organization · Istanbul, Istanbul · NCT07390279

• Venlafaxine to prevent postherpetic neuralgia after shingles

  This study will test whether giving venlafaxine to adults with recent shingles reduces the chance of developing postherpetic neuralgia.

  Recruiting Beijing Tiantan Hospital · Beijing · NCT07361796

• Y-4 for postherpetic neuralgia

  This will test whether Y-4 reduces nerve pain in adults with postherpetic neuralgia compared with pregabalin.

  Recruiting Phase 2 Neurodawn Pharmaceutical Co., Ltd. · Nanjing, Jiangsu · NCT07275762

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.